Lipoproteins and Cardiovascular Health

Lipoproteins are particles that ferry cholesterol and fats through the bloodstream, and their behavior—particularly the accumulation of low-density lipoprotein (LDL) cholesterol in arterial walls—sits at the center of atherosclerosis, the underlying process behind most heart attacks and strokes. Statins, the most widely prescribed class of cholesterol-lowering drugs, reduce LDL and also appear to dampen inflammation, as reflected by lower levels of C-reactive protein, though the relative contribution of these two mechanisms to cardiovascular protection remains actively debated. Large-scale clinical trials and meta-analyses have established clear thresholds for treating hypercholesterolemia, yet researchers continue to refine who benefits most from statin therapy and at what stage of atherosclerotic risk intervention is warranted. Newer agents and genetic studies of familial hypercholesterolemia are pushing the boundaries of how low LDL can safely go, raising fresh questions about long-term outcomes beyond what existing trial data can yet answer.

Works

116,676

Total citations

2,159,033

Keywords

Cholesterol-loweringStatinsCardiovascular Disease PreventionLDL CholesterolClinical TrialsAtherosclerotic Cardiovascular Risk